Welcome to our dedicated page for EUDA Health Holdings SEC filings (Ticker: EUDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on EUDA Health Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into EUDA Health Holdings's regulatory disclosures and financial reporting.
EUDA Health Holdings Limited has filed a resale prospectus covering up to 947,963 ordinary shares, including 7,306 shares issuable upon exercise of 292,250 warrants. All shares may be sold from time to time by existing shareholders; the company is not selling shares and will not receive resale proceeds.
The registered shares include 500,000 shares issued under a Simple Agreement for Future Tokens with QB Limited and shares held by affiliates. Ordinary shares outstanding were 2,994,325 as of July 31, 2026, or 3,001,631 assuming full exercise of the registered warrants.
EUDA distributes non-invasive healthcare products and property management services in Asia and is developing a digital health and rewards platform integrating QB Utility Tokens. EUDA discloses recurring losses, a going concern explanatory paragraph, and a material weakness in internal control over financial reporting, alongside extensive risks related to token integration, reliance on third parties, regulation and capital needs.
EUDA Health Holdings Limited has filed an amended Form F-3 to register the resale of up to 947,963 ordinary shares by existing shareholders. The shares comprise 500,000 shares issued under a Simple Agreement for Future Tokens with QB Limited, 440,657 shares held by affiliates, and 7,306 shares issuable upon exercise of 292,250 outstanding warrants.
EUDA will not receive any proceeds from these sales, though it will cover registration expenses. The business now centers on property management and a growing wellness distribution arm following the discontinuation of medical services. The company reports recurring losses, a going-concern explanatory paragraph, and a material weakness in internal controls, and expects to need additional capital.
The filing also details a planned digital health and rewards platform integrating QB Utility Tokens, of which EUDA purchased 16 million tokens for ecosystem use. Token issuance, supply and governance remain under QB Limited’s control, and extensive risk factors highlight operational, regulatory, liquidity and technology risks around both the core business and the token-based platform.
EUDA Health Holdings Limited describes a planned collaboration under a non-binding Memorandum of Understanding with GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology Co., Ltd. The parties plan to combine GO POSB’s induced pluripotent stem cell platform and universal tumor organoid bank with SIIT’s Natural Killer and NK-TCR cell engineering and GMP manufacturing capabilities to explore off-the-shelf cell therapies for wellness and oncology.
The initiative targets future global distribution, subject to definitive agreements, sufficient funding, manufacturing, testing, clinical evaluation and regulatory approvals. EUDA positions this program within its strategy as a distributor of wellness and non-invasive healthcare products in Asia, aiming to address the needs of over 1.8 billion people in a region where more than 30% of the population is rapidly aging.
EUDA Health Holdings Limited entered into a tri-party Memorandum of Understanding with GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology Co., Ltd. to collaborate on next-generation therapies derived from induced pluripotent stem cells, including NK-TCR cell therapies.
The company states this collaboration is a significant milestone that aligns with its strategy to strengthen commercialization and distribution of innovative, science-backed wellness and non-invasive healthcare products and services. EUDA focuses on Singapore, Malaysia and China and aims to serve over 1.8 billion people in a region where more than 30% of the population is rapidly aging, with an emphasis on the longevity sector.
Euda Health Holdings Limited reports that it has terminated its at-the-market equity offering program and the related At The Market Offering Agreement with Chardan Capital Markets, LLC. The program had previously allowed sales of ordinary shares with an aggregate offering price of up to $10.0 million, but this capacity had been reduced to zero and no ordinary shares were sold. All related prospectus supplements are also terminated as of the date of this supplement. The company’s ordinary shares trade on the NASDAQ Capital Market under the symbol EUDA, and the closing price was $15.30 on July 21, 2026.
EUDA Health Holdings Limited, a British Virgin Islands company listed on Nasdaq, has filed an amended Form F-3 to register the resale of up to 947,963 ordinary shares. These consist of 500,000 shares issued under a Simple Agreement for Future Tokens with QB Limited, 440,657 shares held by affiliates, and 7,306 shares issuable from 292,250 warrants held by a significant shareholder. EUDA is not selling shares and will receive no proceeds from these resales, though it will bear registration costs.
EUDA distributes non-invasive healthcare products and services in Singapore, Malaysia and China, but currently derives most revenue from property management services while building a wellness-focused business. It acquired CK Health in 2024 and is developing an integrated digital health and rewards platform that will use QB Utility Tokens as a loyalty medium; EUDA purchased 16 million tokens for internal platform use but does not control their issuance or market trading.
The company reports recurring losses, a going-concern explanatory paragraph, a working capital deficit, and a material weakness in internal control over financial reporting. It expects to need additional external financing and highlights extensive risks around its distribution model, third-party manufacturers, token integration, regulatory changes, and potential PFIC status.
EUDA Health Holdings Limited filed an amendment to a Form F-3 registration statement to register up to 947,963 ordinary shares for resale by identified selling shareholders.
The 947,963 Shares consist of 500,000 shares issued under the QB Agreement, 440,657 shares held by affiliates, and 7,306 Warrant Shares issuable upon exercise of 292,250 warrants at an exercise price of $230.00 per share. The company will not receive proceeds from sales by the selling shareholders. Ordinary shares outstanding after this offering are stated as 3,001,631.
EUDA Health Holdings filed a prospectus supplement to amend its prior ATM registration, reducing the maximum aggregate offering price to $10.0 million and suspending further sales under the ATM Agreement. The company states that no ordinary shares have been sold under the ATM Agreement as of the date of this Supplement. The company notified the manager on June 5, 2026 of its intent to terminate the ATM Agreement; the termination becomes effective 30 business days after that notice per the agreement. The supplement notes the Nasdaq closing price of the ordinary shares was $15.50 on June 11, 2026.